Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

Home

/

VSTM

V

Verastem, Inc. (VSTM)

NCM – Real Time Price. Currency in USD

6.95

-0.10 (-1.42%)

At close: Aug 12, 2026, 4:00 PM EDT

6.92

-0.03 (-0.43%)

After-hours: Aug 12, 2026, 5:12 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Verastem Q2 Earnings Call Highlights

Verastem Q2 Earnings Call Highlights

Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.39 per share a year ago.

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.

Videos

No Data

There is no data to display

Press releases

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.